is the primary treatment at the onset of the disease in patients with recurrent, metastatic, or unresectable GISTs.
Tenders are invited for Imatinib mesylate
Cancer medicines company Mylan NV (Nasdaq:MYL)(TASE:MYL) reported on Friday the availability of Imatinib Mesylate
Tablets in 100 mg and 400 mg.
M2 EQUITYBITES-October 2, 2017-Mylan launches Imatinib Mesylate
Tablets in US
(Glivec[R], STI 571; Novartis Pharma, Switzerland), an antitumor agent has been widely used to treat multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia and gastrointestinal stromal tumors.
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate
for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
product known by its chemical name of imatinib mesylate
The company is expected to launch the generic version of imatinib mesylate
Debulking large lesions is helpful when adjuvant therapy with imatinib mesylate
Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate
in chronic myeloid leukemia.
The patient was started on imatinib mesylate
400 mg daily and is on regular follow up.
These advances led to the development of molecular targeted therapy for adjuvant and neoadjuvant protocols, using tyrosine kinase inhibitors like imatinib mesylate